Larson Financial Group’s Corcept Therapeutics CORT Stock Holding History

Larson Financial Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.02K	Buy	75 +8	+12%	+$299	﹤0.01%	2828
2025 Q4	$2.33K	Sell	67 -394	-85%	-$30.9K	﹤0.01%	2731
2025 Q3	$38.3K	Buy	461 +442	+2,326%	+$32K	﹤0.01%	1277
2025 Q2	$1.4K	Buy	19 +4	+27%	+$290	﹤0.01%	2536
2025 Q1	$1.71K	Buy	15 +3	+25%	+$183	﹤0.01%	2217
2024 Q4	$605	Buy	12 +4	+50%	+$210	﹤0.01%	2152
2024 Q3	$370	Hold	8	–	–	﹤0.01%	2208
2024 Q2	$260	Buy	+8	New	+$219	﹤0.01%	1999

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Larson Financial Group's CORT Position: Q1 2026 in Review

Larson Financial Group increased its Corcept Therapeutics (CORT) stake by 12% in Q1 2026, buying an estimated $299 and bringing the position to 75 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Larson Financial Group first reported a position in CORT in Q2 2024 and has held it in 8 quarters since. The position peaked at $38.3K in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Larson Financial Group held 75 shares of Corcept Therapeutics worth $3.02K as of Q1 2026.
Larson Financial Group bought 8 Corcept Therapeutics shares in Q1 2026, an estimated $299.
Corcept Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2828 holding.
Larson Financial Group first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 8 quarters since.
Larson Financial Group's Corcept Therapeutics position peaked at $38.3K in Q3 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.